NEWSROOM

SS Innovations Announces Strategic Partnership with Surgical Lab for Distribution in Africa

SS Innovations Announces Strategic Partnership with Surgical Lab for Distribution in Africa

Pan African Medical Device Distributor Surgical Lab to place the SSi Mantra Surgical Robotic System in Healthcare Facilities across the African Continent Surgical Lab has Begun Registration of SSi Mantra in 27 African countries FORT LAUDERDALE, FL, December 26, 2023 - SS Innovations International, Inc. (the "Company" or "SS Innovations") (OTC:SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population,...

read more
PRISM MediaWire – Weekly Press Resume – Dec. 18 to Dec. 22, 2023

PRISM MediaWire – Weekly Press Resume – Dec. 18 to Dec. 22, 2023

New York, December 22, 2023 PRISM MediaWire - Weekly Press Resume Dec. 18 to Dec. 22, 2023 SinglePoint Rings the Opening Bell at Cboe Global Markets Exchange https://prismmediawire.com/singlepoint-rings-the-opening-bell-at-cboe-global-markets-exchange/ MindMed Advances Treatment for Generalized Anxiety Disorder https://prismmediawire.com/mindmed-advances-treatment-for-generalized-anxiety-disorder/ PRISM Analysis: Why Did Battalion Oil Shares Soar on Friday?...

read more
HOOKIPA Stock Jumps Following $21.25M Gilead Equity Investment

HOOKIPA Stock Jumps Following $21.25M Gilead Equity Investment

New York, December 22, 2023 - Gilead Sciences (Nasdaq: GILD) has purchased 15 million shares of immunotherapeutics company, HOOKIPA Pharma’s (Nasdaq: HOOK), common stock for approximately $21.25 million, at a price of $1.4167 per share. Under the agreement, HOOKIPA is responsible for advancing its HIV program through the completion of a Phase 1b clinical trial. The company’s shares rose 52.65% on Thursday and 80.51% premarket on Friday. https://prismmarketview.com/companies/hookipa-pharma-inc/...

read more
PRISM Analysis: PetVivo Holdings Achieves Distribution Milestone; Shares Soar 40%

PRISM Analysis: PetVivo Holdings Achieves Distribution Milestone; Shares Soar 40%

New York, December 22, 2023 - PetVivo Holdings, Inc. (Nasdaq: PETV) has achieved a distribution milestone, reporting a total of 4500 syringes of Spryng™ with OsteoCushion™ technology distributed to veterinarians in the 2023 calendar year. https://prismmarketview.com/companies/petvivo-holdings-inc/ Spryng, the company’s signature product, helps to manage lameness, joint pain and osteoarthritis in horses and small animals. Earlier this month, the company announced the sale of Spryng to more...

read more
PRISM Analysis: Why Did CareCloud Shares Jump This Week?

PRISM Analysis: Why Did CareCloud Shares Jump This Week?

New York, December 22, 2023 - Healthcare technology solutions provider, CareCloud, Inc. (Nasdaq: CCLD) has seen a jump in its share price this week. The new momentum is being driven by the company’s financial and operational update, issued on Wednesday, and outlining an attractive roadmap for future growth. Shareholders rewarded CareCloud with a 25.61% increase following Wednesday’s session, and a 22.94% boost on Thursday. https://prismmarketview.com/companies/carecloud-inc/ Remarking on the...

read more
Spooz, Inc. (SPZI) / JP Energy / John K. Park – announce Shareholder Letter

Spooz, Inc. (SPZI) / JP Energy / John K. Park – announce Shareholder Letter

Clearwater, FL., December 21, 2023 -- Spooz, Inc. (OTC: SPZI) announces the release of the following shareholder letter: Dear Spooz Shareholder, By now, you are aware that I recently became the Chairman and CEO of Spooz. I am a 63-year-old Korean businessman and a US Citizen. I received my MBA from Rutgers University 24 years ago and have headquartered my businesses in the US, mostly in NJ, which includes Student Housing for Rutgers University students, Residential Multifamily apartments,...

read more
Ring In The New Year with Traditions and Trades: Cultural Celebrations and Stock Plays for a Prosperous Start

Ring In The New Year with Traditions and Trades: Cultural Celebrations and Stock Plays for a Prosperous Start

New York, December 21, 2023 - In two weeks, 2023 will be history so consider this your reminder to start figuring out a resolution that likely will be forgotten, by this time next year. New Years is celebrated in a multitude of ways based on geography, culture, or religion. However, unlike other holidays, it is one that is observed by mostly everyone around the world. As always, PRISM has you covered as we close out the year and provide you with some “go-to” resolution ideas, highlight some...

read more
Palatin Technologies Sells Vyleesi in $171M Transaction

Palatin Technologies Sells Vyleesi in $171M Transaction

New York, December 21, 2023 - Palatin Technologies, Inc. (NYSE American: PTN) has completed the sale of Vyleesi® to Cosette Pharmaceuticals, a US-based, specialty pharmaceutical company, for up to $171 million. Vyleesi is the first and only as-needed FDA-approved treatment for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). https://prismmarketview.com/companies/palatin-technologies-inc/ Carl Spana, Ph.D., President and Chief Executive Officer of...

read more
SinglePoint CEO Releases Shareholder Letter Overviewing 2023 and Successful Listing on Cboe BZX Exchange

SinglePoint CEO Releases Shareholder Letter Overviewing 2023 and Successful Listing on Cboe BZX Exchange

Successfully Uplisted to Cboe BZX Exchange December 15, 2023 Year to Date Revenue Crossing $30 million Completed $4,000,000 Underwritten Offering Capital Raise Phoenix, AZ, December 21, 2023 - SinglePoint Inc. (Cboe: SING) a leading renewable solar energy and sustainable solutions provider releases shareholder letter overviewing 2023 and Successful listing on Cboe BZX Exchange. Dear Shareholders, As we approach the end of a tough yet remarkable year, I am pleased to share a comprehensive...

read more
Creative Medical Technology Granted FDA Clearance for Chronic Back Pain Clinical Trial

Creative Medical Technology Granted FDA Clearance for Chronic Back Pain Clinical Trial

New York, December 21, 2023 - Creative Medical Technology Holdings, Inc. (Nasdaq: CELZ) has received FDA clearance to conduct a phase 1/2 clinical trial using the company’s innovative StemSpine® treatment known as AlloStem™ (CELZ-201-DDT). https://prismmarketview.com/companies/creative-medical-technology-holdings-inc/ Timothy Warbington, CEO of Creative Medical Technology, said, “The FDA’s clearance and IRB approval allowing us to pursue this clinical trial is another...

read more

Contact Us

PRISM MediaWire
info@prismmediawire.com
Phone: 646-780-8850